InvestorsHub Logo
Followers 90
Posts 17902
Boards Moderated 0
Alias Born 09/06/2006

Re: ATLnsider post# 573077

Friday, 03/03/2023 9:42:33 PM

Friday, March 03, 2023 9:42:33 PM

Post# of 725040
You do know that the DCVax-L results for methylated patients were no better than the 548 trial in methylated patients, right?

mOS was 32.1 in 548 placebo
mOS was 30.2 in DC treatment methylated patients

By 4 years the DC arm would pull ahead some, but not enough to overcome the earlier numbers.

The 548 trial excluded biopsies and partial biopsies of under 20%. That makes it more inclusive the ECA patients but not as strict as the DC treatment arm.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News